BM‐MNCs vs mPBSCs
- Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical… 2018 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 202 participantsGRADE not reported
It is very uncertain whether high cell dose changes amputation rate Assessed during in‐patient stay (Losordo 2012) compared with low cell dose (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
BM‐MNCs showed no clear difference in amputation rate Assessed during in‐patient stay compared with mPBSCs (low certainty).
IM injection showed no clear difference in amputation rate Assessed during in‐patient stay compared with IA injection (low certainty).
IM injection showed no clear difference in wound/ulcer healing: number of participants with healing ulcer compared with IA injection (low certainty).
IM injection showed no clear difference in reduction in rest pain: number of participants with reduction in… compared with IA injection (low certainty).
It is very uncertain whether IM injection changes improvement in lower limb perfusion: number of participants with… compared with IA injection (very low certainty).
It is very uncertain whether IM injection changes improvement in lower limb perfusion: number of participants with… compared with IA injection (very low certainty).
BM‐MNCs showed no clear difference in wound/ulcer healing: number of participants with healing ulcers… compared with mPBSCs (low certainty).
BM‐MNCs showed no clear difference in reduction in rest pain: number of participants with any reduction in… compared with mPBSCs (moderate certainty).
BM‐MNCs showed no clear difference in improvement in lower limb perfusion: number of participants with… compared with mPBSCs (low certainty).